Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Anika Therapeutics (ANIK) Gross Margin: 2010-2025

Historic Gross Margin for Anika Therapeutics (ANIK) over the last 15 years, with Sep 2025 value amounting to 56.02%.

  • Anika Therapeutics' Gross Margin fell 964.00% to 56.02% in Q3 2025 from the same period last year, while for Sep 2025 it was 54.74%, marking a year-over-year decrease of 2007.00%. This contributed to the annual value of 63.38% for FY2024, which is 494.00% down from last year.
  • According to the latest figures from Q3 2025, Anika Therapeutics' Gross Margin is 56.02%, which was up 10.07% from 50.90% recorded in Q2 2025.
  • Anika Therapeutics' Gross Margin's 5-year high stood at 66.69% during Q2 2024, with a 5-year trough of -199.14% in Q4 2023.
  • Its 3-year average for Gross Margin is 36.67%, with a median of 60.16% in 2023.
  • As far as peak fluctuations go, Anika Therapeutics' Gross Margin tumbled by 18,607bps in 2022, and later surged by 25,510bps in 2024.
  • Quarterly analysis of 5 years shows Anika Therapeutics' Gross Margin stood at 50.62% in 2021, then tumbled by 18,607bps to -135.45% in 2022, then crashed by 6,369bps to -199.14% in 2023, then spiked by 25,510bps to 55.96% in 2024, then plummeted by 964bps to 56.02% in 2025.
  • Its Gross Margin stands at 56.02% for Q3 2025, versus 50.90% for Q2 2025 and 56.10% for Q1 2025.